Immunotherapy with interferons may induce neuropsychiatric symptoms and disorders. Interferon-α-based immunotherapy is used to treat patients with chronic hepatitis C and metastatic renal cell carcinoma. Immunotherapy with interferon-α induces symptoms such as slowness, severe fatigue, hypersomnia, lethargy, depressed mood, mnemonic troubles, irritability, short temper, emotional lability, social withdrawal, lack of concentration and full blown major depression in a considerable number of patients treated. The exact mechanism whereby interferon-α induces depression has remained elusive. However, there is now some evidence that interferon-α-based immunotherapy induces the cytokine network, decreases the serotonergic turnover in the brain, and induces the catabolism of tryptophan. There is evidence that interferon-α immunotherapy-induced depression is related to an increased catabolism of tryptophan into kynurenine.
Stefania Bonaccorso, Valentina Marino, Antonella Puzella, Massimo Pasquini, Massimo Biondi, Marco Artini, C. Almerighi, Robert Verkerk, Herbert Y. Meltzer, Michael Maes
Francisco Stefânio Barreto, Adriano José Maia Chaves Filho, Márcia Cristiane Araújo, Manoel O. de Moraes, Maria Elisabete Amaral de Moraes, Michael Maes, David Freitas de Lucena, Danielle S. Macêdo
Arthur R. Van Gool, Heidi H. van Ojik, Wim H.J. Kruit, Paul Mulder, Durk Fekkes, M. Bannink, Simon Scharpé, G. Stoter, A.M.M. Eggermont, Michael Maes, Robert Verkerk
Discussion(0)
No comments yet. Be the first to comment.